PEGYLATED INTERFERON LAMBDA (PEG-IFN-lambda) PHASE 2 DOSE-RANGING, ACTIVE-CONTROLLED STUDY IN COMBINATION WITH RIBAVIRIN (RBV) FOR TREATMENT-NAiVE HCV PATIENTS (GENOTYPES 1, 2, 3 OR 4): SAFETY, VIRAL RESPONSE, AND IMPACT OF IL-28B HOST GENOTYPE THROUGH WEEK 12
Publication
, Conference
Muir, AJ; Lawitz, E; Ghalib, RH; Sussman, NL; Anderson, F; Everson, GT; Jacobson, IM; Lopez-Talavera, JC; Hillson, JL; Gray, TE; Fontana, D ...
Published in: HEPATOLOGY
October 1, 2010
Duke Scholars
Published In
HEPATOLOGY
ISSN
0270-9139
Publication Date
October 1, 2010
Volume
52
Issue
4
Start / End Page
715A / 716A
Location
Boston, MA
Publisher
WILEY-BLACKWELL
Conference Name
61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases
Related Subject Headings
- Gastroenterology & Hepatology
- 3204 Immunology
- 3202 Clinical sciences
- 1107 Immunology
- 1103 Clinical Sciences
- 1101 Medical Biochemistry and Metabolomics
Citation
APA
Chicago
ICMJE
MLA
NLM
Muir, A. J., Lawitz, E., Ghalib, R. H., Sussman, N. L., Anderson, F., Everson, G. T., … Rodriguez-Torres, M. (2010). PEGYLATED INTERFERON LAMBDA (PEG-IFN-lambda) PHASE 2 DOSE-RANGING, ACTIVE-CONTROLLED STUDY IN COMBINATION WITH RIBAVIRIN (RBV) FOR TREATMENT-NAiVE HCV PATIENTS (GENOTYPES 1, 2, 3 OR 4): SAFETY, VIRAL RESPONSE, AND IMPACT OF IL-28B HOST GENOTYPE THROUGH WEEK 12. In HEPATOLOGY (Vol. 52, pp. 715A-716A). Boston, MA: WILEY-BLACKWELL.
Muir, Andrew J., Eric Lawitz, Reem H. Ghalib, Norman L. Sussman, Frank Anderson, Gregory T. Everson, Ira M. Jacobson, et al. “PEGYLATED INTERFERON LAMBDA (PEG-IFN-lambda) PHASE 2 DOSE-RANGING, ACTIVE-CONTROLLED STUDY IN COMBINATION WITH RIBAVIRIN (RBV) FOR TREATMENT-NAiVE HCV PATIENTS (GENOTYPES 1, 2, 3 OR 4): SAFETY, VIRAL RESPONSE, AND IMPACT OF IL-28B HOST GENOTYPE THROUGH WEEK 12.” In HEPATOLOGY, 52:715A-716A. WILEY-BLACKWELL, 2010.
Muir AJ, Lawitz E, Ghalib RH, Sussman NL, Anderson F, Everson GT, et al. PEGYLATED INTERFERON LAMBDA (PEG-IFN-lambda) PHASE 2 DOSE-RANGING, ACTIVE-CONTROLLED STUDY IN COMBINATION WITH RIBAVIRIN (RBV) FOR TREATMENT-NAiVE HCV PATIENTS (GENOTYPES 1, 2, 3 OR 4): SAFETY, VIRAL RESPONSE, AND IMPACT OF IL-28B HOST GENOTYPE THROUGH WEEK 12. In: HEPATOLOGY. WILEY-BLACKWELL; 2010. p. 715A-716A.
Muir, Andrew J., et al. “PEGYLATED INTERFERON LAMBDA (PEG-IFN-lambda) PHASE 2 DOSE-RANGING, ACTIVE-CONTROLLED STUDY IN COMBINATION WITH RIBAVIRIN (RBV) FOR TREATMENT-NAiVE HCV PATIENTS (GENOTYPES 1, 2, 3 OR 4): SAFETY, VIRAL RESPONSE, AND IMPACT OF IL-28B HOST GENOTYPE THROUGH WEEK 12.” HEPATOLOGY, vol. 52, no. 4, WILEY-BLACKWELL, 2010, pp. 715A-716A.
Muir AJ, Lawitz E, Ghalib RH, Sussman NL, Anderson F, Everson GT, Jacobson IM, Lopez-Talavera JC, Hillson JL, Gray TE, Fontana D, Ramos EL, Rodriguez-Torres M. PEGYLATED INTERFERON LAMBDA (PEG-IFN-lambda) PHASE 2 DOSE-RANGING, ACTIVE-CONTROLLED STUDY IN COMBINATION WITH RIBAVIRIN (RBV) FOR TREATMENT-NAiVE HCV PATIENTS (GENOTYPES 1, 2, 3 OR 4): SAFETY, VIRAL RESPONSE, AND IMPACT OF IL-28B HOST GENOTYPE THROUGH WEEK 12. HEPATOLOGY. WILEY-BLACKWELL; 2010. p. 715A-716A.
Published In
HEPATOLOGY
ISSN
0270-9139
Publication Date
October 1, 2010
Volume
52
Issue
4
Start / End Page
715A / 716A
Location
Boston, MA
Publisher
WILEY-BLACKWELL
Conference Name
61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases
Related Subject Headings
- Gastroenterology & Hepatology
- 3204 Immunology
- 3202 Clinical sciences
- 1107 Immunology
- 1103 Clinical Sciences
- 1101 Medical Biochemistry and Metabolomics